Gastrointestinal Cancers News

Lifestyle Factors Accelerated Age-Related Remodeling of Esophageal Tissue

Lifestyle Factors Accelerated Age-Related Remodeling of Esophageal Tissue

Smoking and drinking were related to changes in the esophageal epithelium.

Surgical Practices May Explain International Survival Differences in Cancer Treatment

Surgical Practices May Explain International Survival Differences in Cancer Treatment

Overall, patient survival was not associated with surgical technique.

Patients Uncomfortable Stopping Colorectal Cancer Screening Despite Low Value

Patients Uncomfortable Stopping Colorectal Cancer Screening Despite Low Value

Some patients may not be comfortable discontinuing colorectal cancer screening despite minimal benefit associated with the testing.

Pilot Study Seeks to Assess Physical Activity Program in Patients With Gastrointestinal Cancer

Pilot Study Seeks to Assess Physical Activity Program in Patients With Gastrointestinal Cancer

Researchers are seeking to assess a physical activity program program in patients with gastrointestinal cancer.

Early Phase 1 Trial Investigating Postoperative Treatment Selection After Preoperative Chemotherapy for Gastric Cancers

Early Phase 1 Trial Investigating Postoperative Treatment Selection After Preoperative Chemotherapy for Gastric Cancers

Researchers are seeking to determine the feasibility of receiving either postoperative chemoradiation or chemotherapy, based on nodal status at surgery.

Phase 1, 2 Trials to Assess Imaging System for Gastrointestinal Cancer Detection

Phase 1, 2 Trials to Assess Imaging System for Gastrointestinal Cancer Detection

Researchers are seeking to assess the initial safety and efficacy of LUM015 imaging of colorectal, pancreatic, and esophageal cancers using the LUM 2.6 imaging device.

Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer

Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer

A clinical trial found a potential marker to identify the patients with advanced esophageal squamous cell carcinoma who were most likely to respond to nivolumab.

HER2 Amplification in Brain Metastases May Be Relatively Common in GI Cancer

HER2 Amplification in Brain Metastases May Be Relatively Common in GI Cancer

Brain metastases were HER2-positive in nearly one-third of patients with gastrointestinal primary malignancies, suggesting molecular testing may be prudent.

Long-Term Surgical Outcomes for Rectal Cancer Survivors Elucidated in Study

Long-Term Surgical Outcomes for Rectal Cancer Survivors Elucidated in Study

Participant characteristics were similar between surgical treatment groups.

Patient Evaluation of Quality in GI Cancer Surgery

Patient Evaluation of Quality in GI Cancer Surgery

Patient-reported quality measures, collected from those who underwent surgery for GI cancer, offered clinicians valuable insight into care management.

Study Found Worse Survival for Patients with Familial Colorectal Cancer Type X

Study Found Worse Survival for Patients with Familial Colorectal Cancer Type X

In patients who developed CRC, those who had familial CRC type X were found to have worse survival outcomes than those who had Lynch syndrome.

BRCA1 Mutation Observed to Confer Heightened Risk of Colorectal Cancer

BRCA1 Mutation Observed to Confer Heightened Risk of Colorectal Cancer

A systematic review and meta-analysis determined that carriers for a mutation to BRCA1, but not BRCA2, have an increased risk of colorectal cancer.

MET Inhibitor as a Monotherapy in GI Cancers: Unlikely Beneficial

MET Inhibitor as a Monotherapy in GI Cancers: Unlikely Beneficial

The study was halted when patient response rates were lower than those seen across a similar trial involving the drug.

Bevacizumab Biosimilar Deemed Bioequivalent to Reference Drug in Metastatic CRC

Bevacizumab Biosimilar Deemed Bioequivalent to Reference Drug in Metastatic CRC

Both the reference product and its biosimilar confer to same benefit, according to research results.

Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma

Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma

Cabozantinib prolonged survival in relapsed HCC across a range of AFP levels, but a larger treatment benefit was observed with higher baseline AFP.

Native Puerto Ricans Are at Increased Risk for Certain Cancers

Native Puerto Ricans Are at Increased Risk for Certain Cancers

Cancer occurrence in island Puerto Ricans and Puerto Ricans living in the continental US and Hawaii differ considerably.

Novel Surrogate End Point Proposed in Hepatocellular Carcinoma

Novel Surrogate End Point Proposed in Hepatocellular Carcinoma

Sustained response duration, as opposed to complete or partial response, may be a better predictor of overall survival in HCC following cTACE.

FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma

FDA Grants Approval to Lenvatinib as First-Line Therapy for Hepatocellular Carcinoma

The FDA based its approval on data from the REFLECT phase 3 study in which investigators enrolled 954 previously untreated patients with metastatic or unresectable hepatocellular carcinoma.

Breakthrough Therapy Designation for Encorafenib, Binimetinib, Cetuximab in BRAFV600E-Mutant CRC

Breakthrough Therapy Designation for Encorafenib, Binimetinib, Cetuximab in BRAFV600E-Mutant CRC

Results from a safety lead-in phase conducted prior to a phase 3 trial examining the safety and tolerability of encorafenib, binimetinib, and cetuximab in combination led the FDA to assign the regimen a breakthrough therapy designation.

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

Twenty-three systemic therapy-naive patients with advanced hepatocellular carcinoma received atezolizumab plus bevacizumab every 3 weeks.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs